International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 13, Issue-12
December, 2023, P14
ISSN: 2319-9253

DIGITAL TWIN INTELLIGENCE IN ONCOLOGY: AI-POWERED VIRTUAL PATIENTS FOR PERSONALIZED TREATMENT OPTIMIZATION

[#1]**Dr. Anand Pillai**, Associate Professor, Department of Internal Medicine,
Meenakshi Medical College Hospital and Research Institute, Kanchipuram, India
Anandpillai42@gmail.com

Abstract: Digital twin intelligence is emerging as one of the most transformative innovations in precision oncology by creating continuously evolving virtual representations of individual cancer patients that integrate multimodal biomedical information to support personalized diagnosis, therapeutic optimization, disease monitoring, and clinical decision-making. Unlike conventional predictive models, digital twins continuously synchronize with real-world patient data, enabling dynamic simulation of disease progression, treatment response, toxicity, recurrence, and survivorship. Recent advances in foundation artificial intelligence (AI) models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled comprehensive integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, biomedical literature, and longitudinal clinical outcomes into adaptive computational patient models. These intelligent virtual patients support biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, adaptive clinical trials, digital biomarker development, and evidence-based multidisciplinary decision support. Emerging technologies including multimodal large language models, agentic AI, federated learning, explainable artificial intelligence, retrieval-augmented generation, cloud-native healthcare infrastructure, and digital health ecosystems further strengthen digital twin intelligence by enabling collaborative, privacy-preserving, transparent, and continuously adaptive computational oncology. Despite remarkable technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interoperability, cybersecurity, clinical validation, governance, and equitable implementation. This review provides a comprehensive overview of digital twin intelligence in oncology, emphasizing AI-powered virtual patients for personalized treatment optimization across the cancer care continuum.[1]

Keywords: *Digital twins, Precision oncology, Foundation models, Artificial intelligence, Virtual patients, Personalized therapeutics, Computational oncology, Digital biomarkers, Clinical decision support, Precision medicine.*

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, stromal remodeling, therapeutic resistance, and intricate interactions among malignant cells, immune populations, vascular structures, extracellular matrix, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of continuously integrating heterogeneous biomedical information.[2]

Modern oncology generates unprecedented volumes of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, biomedical literature, pharmacological databases, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently limits comprehensive understanding of evolving cancer biology and individualized therapeutic decision-making.[3]

Digital twin intelligence addresses these limitations by creating adaptive virtual patients that continuously synchronize with real-world biomedical information, enabling predictive simulation, individualized therapeutic planning, and continuously personalized cancer care.

2. Evolution of Digital Twin Technology in Oncology

Digital twin technology originated within engineering and industrial systems for real-time monitoring of complex physical assets before expanding into biomedical research and healthcare. Early computational patient models primarily represented simplified physiological processes using mathematical simulations with limited personalization. Although valuable for understanding biological mechanisms, these models lacked comprehensive integration of multimodal biomedical information.[4]

Deep learning substantially expanded computational capabilities by enabling automated representation learning from radiological imaging, digital pathology, genomics, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling contextual understanding across heterogeneous biomedical modalities.

Foundation AI models now acquire transferable biomedical knowledge through large-scale self-supervised learning, enabling continuously adaptive digital twins capable of supporting diagnosis, biomarker discovery, therapeutic optimization, disease monitoring, and personalized oncology throughout the cancer care continuum.[5]

3. Principles of Digital Twin Intelligence

Digital twin intelligence differs fundamentally from conventional predictive models because it creates continuously evolving computational representations that remain synchronized with real-world patient biology throughout diagnosis, treatment, and survivorship. Rather than generating isolated predictions, digital twins integrate heterogeneous biomedical information into adaptive patient-specific computational ecosystems capable of simulating disease progression, therapeutic response, toxicity, recurrence, and long-term clinical outcomes.[6]

Foundation AI models acquire generalized biomedical representations through self-supervised learning, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, biomedical literature, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, environmental exposures, and clinical outcomes, thereby enabling systems-level reasoning supporting adaptive virtual patient modeling.[7]

4. Computational Architecture

Modern digital twin oncology platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, multimodal representation learning, adaptive synchronization, predictive simulation, graph reasoning, knowledge integration, and intelligent clinical decision support.[8]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, biomedical literature, pharmacological databases, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1214

processing, synchronize temporal patient information, and continuously incorporate emerging scientific evidence.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, environmental exposures, and longitudinal clinical trajectories while continuously updating virtual patient models throughout precision oncology.[9]

5. Digital Twins for Precision Diagnosis

One of the most important applications of digital twin intelligence is precision diagnosis through continuous integration of multimodal biomedical evidence. Foundation AI models combine radiological imaging, digital pathology, molecular biomarkers, laboratory investigations, genomic alterations, physician documentation, biomedical literature, and clinical guidelines into adaptive virtual patient representations supporting comprehensive diagnostic reasoning.[10]

Digital twins continuously compare newly acquired patient information with previous biological states, enabling early identification of disease progression, emerging therapeutic resistance, evolving molecular alterations, and subtle physiological changes that may remain undetected using conventional diagnostic approaches. Integration of multimodal biomedical information substantially improves diagnostic precision, molecular classification, biomarker interpretation, and individualized oncology.[11]

6. Personalized Treatment Optimization

Digital twin intelligence provides unprecedented opportunities for personalized therapeutic optimization by simulating multiple treatment strategies before clinical implementation. Foundation AI models integrate molecular biomarkers, imaging phenotypes, histopathological findings, laboratory investigations, pharmacological mechanisms, treatment history, physiological monitoring, and patient-specific biological characteristics into continuously evolving computational patient models.[12]

Virtual patient simulations estimate therapeutic responsiveness, treatment-related toxicity, recurrence risk, survival probability, mechanisms of resistance, and long-term clinical outcomes under alternative therapeutic strategies. Reinforcement learning further enables adaptive optimization of treatment sequencing according to continuously evolving patient biology.

These computational capabilities substantially improve precision therapeutics while reducing unnecessary toxicity and supporting individualized treatment planning.[13]

7. Multi-Omics Integration in Digital Twins

Comprehensive digital twin intelligence depends upon seamless integration of complementary molecular technologies including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, single-cell sequencing, spatial transcriptomics, and spatial proteomics. Foundation AI models harmonize these diverse molecular modalities using multimodal transformers and graph neural networks capable of generating generalized molecular representations of evolving tumor ecosystems.[14]

Artificial intelligence identifies latent biological relationships among genes, proteins, metabolites, signaling pathways, immune responses, epigenetic regulation, imaging phenotypes, histopathological architecture, and therapeutic targets while continuously updating digital twin models according to newly acquired biomedical information.

These integrated molecular representations substantially improve biomarker discovery, molecular classification, therapeutic selection, precision immunotherapy, adaptive therapeutics, and translational cancer research.[15]

8. Digital Health and Continuous Patient Synchronization

Digital health technologies including wearable biosensors, mobile health applications, remote physiological monitoring, smart medical devices, patient-reported outcomes, and Internet of Medical Things (IoMT) platforms continuously generate longitudinal physiological information throughout the cancer care continuum. These technologies enable digital twins to remain synchronized with evolving patient physiology beyond traditional healthcare settings.[16]

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1214

Foundation AI models integrate wearable physiological measurements with laboratory biomarkers, molecular biology, radiological imaging, digital pathology, medication adherence, environmental exposures, and electronic health records using multimodal transformer architectures. Continuous synchronization substantially improves early toxicity detection, adaptive disease monitoring, survivorship management, supportive care optimization, and real-world evidence generation.

Digital health therefore represents an indispensable component of intelligent digital twin ecosystems.[17]

9. Adaptive Virtual Patient Intelligence

One of the greatest strengths of digital twin intelligence is its ability to continuously integrate radiology, pathology, multi-omics, laboratory biomarkers, wearable physiological monitoring, biomedical literature, electronic health records, digital biomarkers, patient-reported outcomes, and longitudinal clinical trajectories into adaptive virtual patient representations. Rather than generating static predictive models, intelligent digital twins continuously evolve with the patient, enabling dynamic simulation of disease progression, therapeutic optimization, recurrence prediction, survival estimation, multidisciplinary communication, and precision clinical decision-making. These continuously learning virtual patients establish the computational foundation for personalized oncology, adaptive therapeutics, intelligent clinical decision support, and future precision medicine throughout the entire cancer care continuum.[18][19][20]

10. Knowledge Graph–Enhanced Digital Twins

Knowledge graph technology significantly enhances digital twin intelligence by enabling structured representation of molecular pathways, protein interactions, therapeutic mechanisms, imaging phenotypes, histopathological characteristics, pharmacological knowledge, and longitudinal clinical evidence within adaptive virtual patient models. Foundation AI models integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and biomedical literature into interconnected knowledge graphs that continuously inform digital twin simulations.[21]

Unlike conventional computational models that rely on static datasets, graph-enhanced digital twins dynamically update biological relationships as new evidence becomes available. These interconnected representations enable virtual patients to simulate disease progression, evaluate therapeutic alternatives, anticipate resistance mechanisms, estimate toxicity profiles, personalize supportive care, and predict long-term clinical outcomes according to continuously evolving patient biology.

By integrating graph reasoning with adaptive simulation, knowledge graph–enhanced digital twins transform computational oncology from retrospective prediction toward proactive, adaptive, and continuously personalized precision medicine.

11. Intelligent Clinical Decision Support

Digital twin intelligence provides the computational foundation for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than independently interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines, intelligent virtual patients synthesize diverse biomedical information into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, molecular biomarker analyses, radiomic and pathomic interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, survival predictions, drug interaction analyses, and longitudinal treatment response assessments while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular

DOI : https://doi.org/10.65713/ijaraiv13i1214

biologists, pharmacists, nurses, genetic counselors, biomedical engineers, computational scientists, and healthcare administrators.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Virtual Patients

A defining characteristic of digital twin intelligence is the ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, biomedical literature, pharmacological evidence, clinical guidelines, and real-world clinical outcomes into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic planning, disease monitoring, toxicity management, and survivorship care through iterative evaluation of longitudinal patient outcomes. Digital twins further incorporate clinician feedback, multidisciplinary tumor board recommendations, and evolving biomedical discoveries into continuous model refinement.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of rapidly translating scientific discoveries into individualized patient care.

13. Federated Digital Twin Networks

Development of highly generalizable digital twin platforms requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, wearable ecosystems, treatment protocols, and patient populations. Federated learning enables collaborative development of virtual patient models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local digital twin models using radiological imaging, digital pathology, genomics, transcriptomics, proteomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, transparency, and generalizability across diverse healthcare environments.

Federated digital twin ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, reducing institutional bias, and supporting global cancer research while maintaining responsible biomedical data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of digital twin intelligence requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand digital twin reasoning through attention visualization, pathway mapping, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, confidence calibration, multimodal attention mapping, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, pharmacological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, transparent reporting standards, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, fairness, equitable access, responsible data governance, continuous post-deployment surveillance, clinician education, and multidisciplinary oversight to ensure trustworthy integration of digital twin intelligence into routine oncology practice.

15. Future Perspectives

Future digital twin ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, biomedical knowledge graphs, autonomous reasoning systems, and retrieval-augmented generation into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, pharmacological databases, global clinical guidelines, and real-world clinical outcomes while autonomously coordinating personalized diagnostics, adaptive therapeutics, survivorship management, multidisciplinary communication, patient education, clinical trial optimization, and continuous evidence synthesis.

Such intelligent virtual patient ecosystems are expected to transform oncology from fragmented disease management toward predictive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Digital twin intelligence represents one of the most significant paradigm shifts in computational oncology by integrating radiology, pathology, multi-omics, laboratory biomarkers, wearable health technologies, biomedical literature, digital biomarkers, knowledge graphs, and foundation AI models into adaptive virtual patient ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional predictive algorithms that provide static analyses, digital twins continuously synchronize with evolving patient biology while simulating disease progression, therapeutic response, toxicity development, recurrence, and survivorship through integrated multimodal reasoning.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, precision immunotherapy, adaptive therapeutics, remote patient monitoring, federated collaboration, digital health, survivorship management, intelligent clinical trials, knowledge graph integration, and explainable clinical decision support demonstrate the extraordinary potential of digital twin intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, clinician education, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, intelligent virtual patients are expected to become one of the foundational computational infrastructures supporting precision oncology worldwide.

17. Conclusion

Digital twin intelligence is transforming precision oncology by integrating radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable health technologies, electronic health records, digital biomarkers, biomedical knowledge, and foundation AI models into adaptive virtual patient ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and personalized cancer treatment throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, multimodal large language models, explainable artificial

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1214

intelligence, agentic AI, digital twins, and generative artificial intelligence are expected to further strengthen intelligent virtual patient ecosystems, enabling increasingly accurate molecular characterization, predictive clinical reasoning, adaptive therapeutics, continuous disease surveillance, and precision medicine.[29]
Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, nurses, healthcare organizations, policymakers, industry partners, patients, and regulatory agencies will accelerate the responsible implementation of digital twin intelligence. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, facilitate personalized therapeutics, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
3. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
4. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
5. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
6. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
7. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
8. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
9. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
10. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
11. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
12. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
13. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
14. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
15. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using

Volume 13, Issue-12
December, 2023, P14
ISSN: 2319-9253

Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
16. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
17. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
18. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
19. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
20. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
21. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
22. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
23. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
24. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
25. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
26. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
27. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
28. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
29. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
30. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.